MIHAELA STOICA: Open Payments
NPI 1114238318 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 91 payments from 18 companies in 2025. Trend: 2023 $777 · 2024 $850 · 2025 $1,978
Food & beverage: $1,866Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $325 |
| Teva Pharmaceuticals USA, Inc. | 8 | $281 |
| Alkermes, Inc. | 9 | $249 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $219 |
| Corium, LLC | 8 | $206 |
| Otsuka America Pharmaceutical, Inc. | 11 | $143 |
| Lundbeck LLC | 4 | $116 |
| Vanda Pharmaceuticals Inc. | 3 | $91 |
| Supernus Pharmaceuticals, Inc. | 4 | $80 |
| E.R. Squibb & Sons, L.L.C. | 4 | $75 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Azstarys, ARISTADA, AUSTEDO XR, FANAPT, Qelbree.
Industry payments across TX — which companies pay providers there.
